The radiation dose regimen was identical to the FORCE trial (5 × 4 Gy), and no toxicity was observed that could not be explained by the safety profile of Interleukin-2 (e.g. grade I-II thyroiditis in 25% of study subjects). The gene discussed is IL2; the disease is thyroid gland disorder.